Treatment of breast cancer cell lines with the FGFR inhibitor PD 173074 leads to decreased expression of cyclin D1 and a G1 growth arrest [40, 41], hence, providing rationale for cyclin D1 involvement in resistance to FGFR inhibition. Here, CCND1 is linked to breast carcinoma.